For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- Lecture Fees Paid “Purely as Compensation” Would Not Be Subject to Regulation under New Clinical Research Bill: Health Policy Bureau Chief
May 23, 2016
- Govt’s Draft Economic Growth Strategy Embraces Use of Big Data by PMDA
May 20, 2016
- Deregulation Panel Calls for Revisiting Plasma Export Restrictions, Wants Conclusion by FY2018
May 20, 2016
- Clinical Research Bill to Make It Easier for Companies to Provide Unapproved Drugs for Clinical Programs: LDP Lawmaker
May 20, 2016
- Council Determines Parathyroid Hormone Preparation for Hypoparathyroidism Has High Unmet Medical Need
May 20, 2016
- MHLW Raises Caution for Use of Harvoni, 7 Other Hep C Drugs in HBV Carriers
May 19, 2016
- Clinical Research Bill to Enter Diet Deliberations on May 20, Might Be Enacted June 1
May 19, 2016
- MOF Panel Recommends Full Rollout of Cost-Effective Evaluations
May 19, 2016
- LDP Bigwig Questions Costly Meds Reimbursement without Politicians’ Input
May 19, 2016
- Draft of Govt’s Economic, Fiscal Policy Blueprint Mentions “Optimal Use of Innovative Drugs”
May 19, 2016
- Standard Operating Profit Rate for Cost Calculation Pricing Rule Updated to 14.6%: Chuikyo
May 19, 2016
- Pricy Meds Again a Hot Topic at Chuikyo, MHLW Set to Launch Concrete Discussions
May 19, 2016
- AMED Initiates Project to Create Integrated Database for Clinical Genome Information
May 19, 2016
- Industry Opposes to Market Price Survey for Possible 2017 Revision; “No Reason to Conduct Survey if Sales Tax Hike Is Postponed”: FPMAJ Chairman
May 19, 2016
- Chuikyo OKs 16 APIs for Listing on May 25, Novartis’s Melanoma Combo Gets 45% Price Premium
May 18, 2016
- MHLW Advisory Panel to Discuss ASKA’s Hepatic Encephalopathy Treatment on May 30
May 18, 2016
- MHLW Advisory Panel to Discuss Sanofi’s PCSK9 Inhibitor on May 27
May 16, 2016
- Clinical Research Bill OK’ed by Cabinet, Now Up for Diet Deliberations
May 13, 2016
- MHLW Study Group Agrees MID-NET Database Should Be Made Available for Use in Post-Marketing Surveillance
May 13, 2016
- MHLW Panel Snubs 10-Valent Synflorix for Public Immunization Program
May 12, 2016
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…